

The
United
States
of
America



**The Director of the United States
Patent and Trademark Office**

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Michelle K. Lee

Deputy Director of the United States Patent and Trademark Office



US008822429B2

(12) **United States Patent**
Virno et al.

(10) **Patent No.:** **US 8,822,429 B2**
(45) **Date of Patent:** **Sep. 2, 2014**

(54) **CITICOLINE FOR THE TREATMENT OF
GLAUCOMA AND OCULAR HYPERTENSION**

(75) Inventors: **Cristiano Virno**, Rome (IT); **Marco
Malizia**, Rome (IT)

(73) Assignee: **Omikron Italia S.r.l.**, Rome (IT)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 37 days.

(21) Appl. No.: **13/580,181**

(22) PCT Filed: **Feb. 17, 2011**

(86) PCT No.: **PCT/IB2011/050663**

§ 371 (c)(1),
(2), (4) Date: **Aug. 21, 2012**

(87) PCT Pub. No.: **WO2011/101802**

PCT Pub. Date: **Aug. 25, 2011**

(65) **Prior Publication Data**

US 2012/0316128 A1 Dec. 13, 2012

(30) **Foreign Application Priority Data**

Feb. 22, 2010 (IT) RM2010A0071

(51) **Int. Cl.**
A61K 31/70 (2006.01)
A61K 9/00 (2006.01)
A61K 31/7068 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 9/0048** (2013.01); **A61K 31/7068**
(2013.01)

USPC **514/49**; 514/52

(58) **Field of Classification Search**

• None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,773,472 A * 6/1998 Stjemschantz et al. 514/530

OTHER PUBLICATIONS

Oshitari et al., *Neuroreport*, vol. 13 (16), Nov. 2002, pp. 2109-2111.*
Wikipedia—Definition for “Route of Administration”, Nov. 2013.*
Oshitari et al. “Citicoline has a protective effect on damaged retinal
ganglion cells in mouse culture retina” *Neuroreport*, vol. 13, No. 16,
pp. 2109-2111 (Nov. 2002).

Int’l Search Report for PCT/IB2011/050663, one page, mailed Jun.
8, 2011.

Written Opinion for PCT/IB2011/050663, seven pages, mailed Jun.
8, 2011.

International Preliminary Report on Patentability for PCT/IB2011/
050663, 14 pages, mailed Apr. 26, 2011.

* cited by examiner

Primary Examiner — **Traviss C McIntosh, III**

(74) *Attorney, Agent, or Firm* — **Nixon & Vanderhye PC**

(57) **ABSTRACT**

The present invention refers to citicoline and to compositions
containing it for topic use in treating glaucoma and/or ocular
hypertension.

14 Claims, 11 Drawing Sheets